Abstract: Embodiments of the present description provide a connecting device. The device comprises a seed crystal support and a seed crystal rod, and the seed crystal support is connected to one end of the seed crystal rod.

Abstract: Provided are a method and apparatus for determining image depth information, an electronic device, and a medium. The method includes: acquiring first depth information of pixels in a target image output by a first prediction layer; generating the point cloud model of the target image according to the first depth information, and determining initial depth information of the pixels in the target image in a second prediction layer according to the point cloud model; and performing propagation optimization according to the initial depth information, and determining second depth information of the pixels in the target image output by the second prediction layer, where the first prediction layer is configured before the second prediction layer.

Abstract: Provided are a method and apparatus for determining image depth information, an electronic device, and a medium. The method includes: acquiring first depth information of pixels in a target image output by a first prediction layer; generating the point cloud model of the target image according to the first depth information, and determining initial depth information of the pixels in the target image in a second prediction layer according to the point cloud model; and performing propagation optimization according to the initial depth information, and determining second depth information of the pixels in the target image output by the second prediction layer, where the first prediction layer is configured before the second prediction layer.

Abstract: Systems and methods relating to analog-to-digital converters. A delay block receives an input signal at the same time as a coarse ADC (CADC) block. The CADC block produces a multi-bit output and this output is applied to a signal processing block. The delay block delays the input signal from being applied to the signal processing block until the output of the CADC block has been applied/configures the signal processing block. The signal processing block may be a signal shifter, the output of which is ultimately applied to a fine ADC (FADC) block. In an alternative, the signal processing block may be the FADC block. Regardless of the configuration, the output of the CADC is delayed until the output of the FADC block is available. The outputs of the CADC and the FADC blocks are then simultaneously applied to an encoder that produces the overall system output.

Abstract: A system and a method for a nanostructured film including a first layer for reflecting at least a portion of an electromagnetic radiation and a second layer for receiving the remainder of the electromagnetic radiation through the first layer and subsequently reflecting at least a portion of the received electromagnetic radiation through the first layer, wherein two electromagnetic radiations with the same wavelength reflected by the first and second layers respectively are combined to form a strengthened electromagnetic radiation, the wavelength of the strengthened electromagnetic radiation being variable based on the physical property of the first layer.

Abstract: Systems and methods relating to analog-to-digital converters. A delay block receives an input signal at the same time as a coarse ADC (CADC) block. The CADC block produces a multi-bit output and this output is applied to a signal processing block. The delay block delays the input signal from being applied to the signal processing block until the output of the CADC block has been applied/configures the signal processing block. The signal processing block may be a signal shifter, the output of which is ultimately applied to a fine ADC (FADC) block. In an alternative, the signal processing block may be the FADC block. Regardless of the configuration, the output of the CADC is delayed until the output of the FADC block is available. The outputs of the CADC and the FADC blocks are then simultaneously applied to an encoder that produces the overall system output.

Abstract: A metallic structure includes a first plurality of metal particles arranged in an amorphous structure; a second plurality of metal particles arranged in a crystalline structure having at least two grain sizes, wherein the crystalline structure is arranged to receive the amorphous structure deposited thereon; wherein the grain size is arranged in a gradient structure.

Abstract: A system and a method for a nanostructured film including a first layer for reflecting at least a portion of an electromagnetic radiation and a second layer for receiving the remainder of the electromagnetic radiation through the first layer and subsequently reflecting at least a portion of the received electromagnetic radiation through the first layer, wherein two electromagnetic radiations with the same wavelength reflected by the first and second layers respectively are combined to form a strengthened electromagnetic radiation, the wavelength of the strengthened electromagnetic radiation being variable based on the physical property of the first layer.

Abstract: A method for determining personalized near addition value for non-presbyopes, including measuring fusional amplitudes and phoria with at least one addition value, on both eyes of a person at a working distance; finding a mathematical function that predicts the change of a pair of fusional amplitudes and phoria as a function of addition value based on the addition value and the measured fusional amplitudes and phoria; and determining the near addition value according to a suitable relationship between the pair of fusional amplitudes and phoria on the mathematical function.

Abstract: A metal material including a plurality of metal particles arranged in a crystal structure having at least two phases; wherein the at least two phases include a crystalline phase and an amorphous phase, wherein the crystalline phase includes a nanocrystalline phase and the amorphous phase includes a nanoamorphous phase.

Abstract: A metal material including a plurality of metal particles arranged in a crystal structure having at least two phases; wherein the at least two phases include a crystalline phase and an amorphous phase, wherein the crystalline phase includes a nanocrystalline phase and the amorphous phase includes a nanoamorphous phase.

Abstract: A metallic structure includes a first plurality of metal particles arranged in an amorphous structure; a second plurality of metal particles arranged in a crystalline structure having at least two grain sizes, wherein the crystalline structure is arranged to receive the amorphous structure deposited thereon; wherein the grain size is arranged in a gradient structure.

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Abstract: A method for determining personalized near addition value for non-presbyopes, including measuring fusional amplitudes and phoria with at least one addition value, on both eyes of a person at a working distance; finding a mathematical function that predicts the change of a pair of fusional amplitudes and phoria as a function of addition value based on the addition value and the measured fusional amplitudes and phoria; and determining the near addition value according to a suitable relationship between the pair of fusional amplitudes and phoria on the mathematical function.

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.